Dr. Martin Steiner, CEO
Dr. Steiner joined the Company as chief executive officer of SYNIMMUNE GmbH in March 2016.
Prior to joining SYNIMMUNE, Dr. Martin Steiner was an independent consultant to biotechnology and medtech companies. Before that, he was a founder and CEO of ImVisioN Therapeutics GmbH, a biotechnology company focusing on the development of novel immunotherapies for the treatment of allergies and a founder and CEO of EVAX Technologies and Apovia AG, a biotechnology company focused on the prevention and treatment of infectious diseases. Dr. Steiner obtained a Ph.D. in Microbiology and Genetics from the University of Vienna and a Master of Business Administration (MBA) from the University of Michigan.
Dr. Ludger Große-Hovest, Founder and CSO
Dr. Große-Hovest is a founder and chief scientific officer of SYNIMMUNE GmbH.
Prior to founding SYNIMMUNE, Dr. Große-Hovest was Principal Investigator at the University of Tuebingen for the GO-Bio Research Project, which was the basis for the foundation of Synimmune. Before that he was group leader at the Department of Immunology at the University of Tuebingen focusing on the development of novel strategies for the immunotherapy of cancer. Dr. Große-Hovest obtained his Ph.D. in Immunology from the University of Tuebingen.
Dr. Steffen Aulwurm, Founder and Head of Operations
Dr. Aulwurm is a founder of SYNIMMUNE and Head of Operations at SYNIMMUNE GmbH.
Prior to founding SYNIMMUNE, Dr Aulwurm was group leader for GMP-compliant antibody production at the University of Tuebingen. Before that, he was Post Doc at the Hertie-Institute for clinical brain research. Dr. Aulwurm obtained his PhD in Immunology from the University of Tuebingen. Dr. Aulwurm additionally holds a degree in Chemical Engineering from the Nuremberg Institute of Technology.